PARRINGTON; Mark
Patent Applications and Registrations
Patent applications and USPTO patent grants for PARRINGTON; Mark.The latest application filed is for "expression and conformational analysis of engineered influenza hemagglutinin".
- PARRINGTON; Mark - Swiftwater PA
- Parrington; Mark - Bradford CA
- Parrington; Mark - US
- Parrington, Mark - Bradford Ontario CA
- PARRINGTON, MARK - ONTARIO CA
| Patent | Date |
|---|---|
| Expression And Conformational Analysis Of Engineered Influenza Hemagglutinin App 20170121373 - CORTES-GARCIA; Guadalupe ; et al. | 2017-05-04 |
| Replication-defective flavivirus vaccines and vaccine vectors Grant 9,217,158 - Pugachev , et al. December 22, 2 | 2015-12-22 |
| Tumor antigens BFA4 and BCY1 for prevention and / or treatment of cancer Grant 8,946,174 - Berinstein , et al. February 3, 2 | 2015-02-03 |
| Multi-antigen vectors of melanoma Grant 8,911,991 - Berinstein , et al. December 16, 2 | 2014-12-16 |
| Modified CEA/B7 vector Grant 8,562,970 - Parrington , et al. October 22, 2 | 2013-10-22 |
| Modified CEA nucleic acid and expression vectors Grant 8,530,442 - Parrington , et al. September 10, 2 | 2013-09-10 |
| Modified Cea Nucleic Acid And Expression Vectors App 20130101625 - Parrington; Mark ; et al. | 2013-04-25 |
| Tumor Antigens for the Prevention and/or Treatment of Cancer App 20130011422 - Berinstein; Neil ; et al. | 2013-01-10 |
| Modified CEA nucleic acid and expression vectors Grant 8,236,776 - Parrington , et al. August 7, 2 | 2012-08-07 |
| Tumor antigens for prevention and/or treatment of cancer Grant 8,207,314 - Berinstein , et al. June 26, 2 | 2012-06-26 |
| Replication-Defective Flavivirus Vaccine Vectors Against Respiratory Syncytial Virus App 20120128713 - Pugachev; Konstantin V. ; et al. | 2012-05-24 |
| Tumor antigens Bfa5 for prevention and/or treatment of cancer Grant 8,021,664 - Berinstein , et al. September 20, 2 | 2011-09-20 |
| Tumor Antigens Bfa4 And Bcy1 For Prevention And / Or Treatment Of Cancer App 20110117640 - Berinstein; Neil ; et al. | 2011-05-19 |
| Tumor antigens BFA4 and BCY1 for prevention and / or treatment of cancer Grant 7,851,213 - Berinstein , et al. December 14, 2 | 2010-12-14 |
| Modified Cea Nucleic Acid And Expression Vectors App 20100285065 - Parrington; Mark ; et al. | 2010-11-11 |
| Tumor Antigen Bfy3 For Prevention And/or Treatment Of Cancer App 20100278848 - Berinstein; Neil ; et al. | 2010-11-04 |
| Modified CEA nucleic acid and expression vectors Grant 7,786,278 - Parrington , et al. August 31, 2 | 2010-08-31 |
| Modified KSA and Uses Thereof App 20090156519 - Berinstein; Neil ; et al. | 2009-06-18 |
| Tumor Antigens Bfa5 For Prevention And/Or Treatment Of Cancer App 20080138365 - Berinstein; Neil ; et al. | 2008-06-12 |
| Modified Cea/B7 Vector App 20080113928 - Parrington; Mark ; et al. | 2008-05-15 |
| Expressing gp140 fragment of primary HIV-1 isolate Grant 7,220,826 - Sia , et al. May 22, 2 | 2007-05-22 |
| Modified CEA Nucleic Acid and Expression Vectors App 20070082391 - Parrington; Mark | 2007-04-12 |
| Multi-antigen vectors of melanoma App 20060127360 - Berinstein; Neil ; et al. | 2006-06-15 |
| Tumor antigen BFA5 for prevention and / or treatment of cancer App 20050112099 - Berinstein, Neil ; et al. | 2005-05-26 |
| Immunogenic compositions comprising an antigen and a purified m protein from respiratory syncytial virus App 20050037015 - Barber, Brain ; et al. | 2005-02-17 |
| Tumor antigens BFA4 and BCY1 for prevention and / or treatment of cancer App 20040197912 - Berinstein, Neil ; et al. | 2004-10-07 |
| Respiratory syncytial virus vaccine App 20040022800 - Parrington, Mark ; et al. | 2004-02-05 |
| Alphavirus Vectors For Paramyxovirus Vaccines App 20030180257 - PARRINGTON, MARK ; et al. | 2003-09-25 |
| Alphavirus vectors for paramyxovirus vaccines Grant 6,475,780 - Parrington , et al. November 5, 2 | 2002-11-05 |
| RNA respiratory syncytial virus vaccines Grant 6,060,308 - Parrington May 9, 2 | 2000-05-09 |
uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.
While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.
All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.
| 